Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Major malformations with valproic acid.

Gideon Koren1, Alejandro A Nava-Ocampo, Myla E Moretti

  • 1Motherisk Team, Hospital for Sick Children, Toronto.

Canadian Family Physician Medecin De Famille Canadien
|April 28, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Could a first-trimester blood phosphatidylethanol concentration ⩾4 nM be useful to identify women with moderate-to-heavy prenatal alcohol exposure who are at high risk of adverse pregnancy outcomes?

Medical hypotheses·2015
Same author

Simple high-throughput analytical method using ultra-performance liquid chromatography coupled with tandem mass spectrometry to quantify total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol in urine.

Clinical chemistry and laboratory medicine·2015
Same author

Preventive effects of folic acid supplementation on adverse maternal and fetal outcomes.

PloS one·2014
Same author

Dose-response and time-response analysis of total fatty acid ethyl esters in meconium as a biomarker of prenatal alcohol exposure.

Prenatal diagnosis·2014
Same author

Characterization of phosphatidylethanol blood concentrations for screening alcohol consumption in early pregnancy.

Clinical toxicology (Philadelphia, Pa.)·2014
Same author

Fetal and neonatal outcomes in women reporting ingestion of licorice (Glycyrrhiza uralensis) during pregnancy.

Planta medica·2013
Same journal

Impact of virtual case conferences between primary care clinicians and an interdisciplinary chronic pain clinic.

Canadian family physician Medecin de famille canadien·2026
Same journal

Canadian family physician Medecin de famille canadien·2026
Same journal

Predictors of high-performing family medicine clinics: Prospective cohort study in Alberta.

Canadian family physician Medecin de famille canadien·2026
Same journal

Acetylsalicylic acid use for artial fibrillation and bleeding risk.

Canadian family physician Medecin de famille canadien·2026
Same journal

Clinical practice guidelines: Important tools to teach the art of medicine.

Canadian family physician Medecin de famille canadien·2026
Same journal

Paratonia in advanced dementia: Challenges and evidence-based interventions.

Canadian family physician Medecin de famille canadien·2026
See all related articles

Valproic acid use in pregnancy is linked to major malformations beyond neural tube defects (NTDs). The risk increases with dosage, particularly above 1000 mg/d, compared to other antiepileptics or the general population.

Area of Science:

  • Obstetrics and Gynecology
  • Pharmacology
  • Teratology

Background:

  • Valproic acid is increasingly prescribed for pregnant patients with epilepsy and psychiatric conditions.
  • Existing data primarily highlight the risk of neural tube defects (NTDs) associated with valproic acid.
  • The full spectrum of teratogenic risks requires further investigation.

Purpose of the Study:

  • To determine if valproic acid is associated with teratogenic risks beyond neural tube defects (NTDs) in pregnant patients.
  • To quantify the risk of major malformations in offspring exposed to valproic acid during pregnancy.

Main Methods:

  • Systematic review of all available cohort studies addressing valproic acid teratogenicity.
  • Comparative risk analysis against other antiepileptic drugs and the general population.

Related Experiment Videos

Main Results:

  • Most studies in the systematic review indicated higher rates of major malformations, not limited to NTDs.
  • The relative risk of major malformations was 2.59 compared to other antiepileptic drugs.
  • The relative risk was 3.77 compared to the general population.
  • A dose-dependent risk was observed, with increased risks noted at doses ≥600 mg/d and more prominently at doses >1000 mg/d.

Conclusions:

  • Valproic acid is associated with an increased risk of major malformations in offspring, extending beyond NTDs.
  • The teratogenic risk of valproic acid is dose-dependent.
  • Healthcare providers should carefully consider the risks and benefits of valproic acid in pregnant patients.